Combination treatment with metformin and spironolactone in patients with polycystic ovary syndrome

Ruofei Zhao,Yajuan Li,Qiang Dai,Hong Li,Bimin Shi
DOI: https://doi.org/10.3969/j.issn.1004-583X.2016.10.022
2016-01-01
Abstract:Objective To investigate the effect of combination therapy with metformin and spironolactone in patients with polycystic ovary syndrome,including metabolism,endocrine-related impacts,and subsequent ovulation rates.Methods A total of 60 patients with polycystic ovary syndrome were included in this study.All patients were randomly divided into A and B groups (30 cases each).Group A was treated with metformin 1 000 mg everyday while group B was treated with metformin 1 000 mg combined with spironolactone 40 mg for 3 months.Then related indices were compared before and after treatment between two groups.Results After 3 months of treatment,body mass and BMI were decreased in both groups and were significantly lower than those before treatment (P <0.05);The waist-hip ratio(WHR)and Ferriman-Gallwey score were significantly lower after treatment in group B than in group A (P <0.05). After treatment,the levels of LH and T were decreased and were significantly lower than those before treatment (P <0.05),however,the level of FSH was slightly changed (P > 0.05 ).After treatment,the level of insulin was significantly decreased in group A (P <0.05),however,the level of glucose was no obvious difference(P >0.05);in group B,the levels of insulin and glucose were significantly decreased (P <0.01 and P <0.05,respectively).After treatment,the levels of TG and LDL-C were significantly decreased in group A (P < 0.05 )and the levels of TG, LDL-C and TC were significantly decreased in group B (P <0.05,P <0.01 and P <0.05,respectively).Conclusion In comparison with metformin alone,the combination therapy may be more effective for PCOS patients.
What problem does this paper attempt to address?